Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + paclitaxel + ramucirumab in second-line metastatic gastroesophageal adenocarcinoma
2018-002938-20Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of avelumab, paclitaxel and ramucirumab in gastroesophageal junction adenocarcinoma, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Overall survival rate at 6 months. Started Dec 2018; status: completed.
02
Drugs
avelumabpaclitaxelramucirumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-002938-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002938-20.